Overcoming the barrier treatment of ichthyosis: A combination-therapy approach

Journal of Clinical and Aesthetic Dermatology

Volumn 3, Issue 7, 2010, Pages

  Bellew, Susun ^a   Del Rosso, James Q ^a  

^a VALLEY HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM LACTATE; CERAMIDE; CHOLESTEROL; EPICERAM; EPICERAM SKIN BARRIER EMULSION; FATTY ACID; UNCLASSIFIED DRUG;

ARTICLE; CASE REPORT; CHILD; CLINICAL FEATURE; CREAM; DRUG EFFICACY; HUMAN; ICHTHYOSIS VULGARIS; LIPID BILAYER; LOTION; MALE; PATHOPHYSIOLOGY; SCHOOL CHILD; STRATUM CORNEUM; SYMPTOM; TREATMENT OUTCOME;

EID: 77957595028     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Oji V, Traupe H. Ichthyosis. Clinical manifestations and practical treatment options. Am J Clin Dermatol. 2009;10(6):351-364.
2. Akiyama M, Shimizu H. An update on molecular aspects of the non-syndromic ichthyoses. Exp Dermatol. 2008;17: 373-382.
3. Smith FJ, Irvine AD, Terron-Kwiatkowski, et al. Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. Nat Genet. 2006;38:337-342.
4. McGrath J. Filaggrin and the great epidermal barrier grief. Australas J Dermatol. 2008;49(2):67-73.
5. Sybert VP, Dale BA, Holbrook KA. Ichthyosis vulgaris: identification of a defect in synthesis of filaggrin correlated with an absence of keratohyaline granules. J Invest Dermatol. 1985;84:191-194.
6. Schmuth M, Gruber R, Elias P. Ichthyosis update: towards a function-driven model of pathogenesis of the disorders of cornification and the role of corneocyte proteins in these disorders. Adv Dermatol. 2007;23:231-256.
7. Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38:44-46.
8. Sandilands A, Terron-Kwiatkowski A, Hull PR, et al. Comprehensive analysis of the gene encoding filaggrin uncovers prevalent and rare mutations in ichthyosis vulagris and atopic eczema. Nat Genet. 2007;39(5):650-654.
9. Scleuplein RJ, Blank IH. Permeability of the skin. Phsiol Rev. 1971;51(4):702-747.
10. Harding CR, Watkinson A, Rawlings AV. Dry skin, moisturization and corneodesmolysis. Int J Cosmet Sci. 2000;22:21-52.
11. Elias PM. Epidermal lipids, barrier function and desquamation. J Invest Dermatol. 1983;80(suppl 1):44-49.
12. Menon GK, Norlen L. Stratum corneum ceramides and their role in skin barrier function. In: Leyden J, Rawlings A, eds. Skin Moisturization. New York: Marcel Dekker Inc.; 2002:40-55.
13. Nemes Z, Steinert PM. Bricks and mortar of the epidermal barrier. Exp Mol Med. 1999;31(1):5-19.
14. Cler EJ, Fourtanier A. L'acide pyrrolidone carboxylique (PCA) et la peau. Int J Cosmet Sci. 1981;3:101-113.
15. Rawlings AV, Harding CR. Moisturization and skin barrier function. Dermatol Ther. 2004;17 (suppl 1):43-48.
16. Bouwstra JA, Dubbelaar FER, Gooris GS, et al. The role of ceramide composition in the lipid organization of the skin barrier. Biochim Biophys Acta. 1999;1419:127-136.
17. Norlen L, Nicander I, Lundh-Rozell B, et al. Inter and intra individual differences in stratum corneum lipid content related to physical parameters of skin barrier function in-vivo. J Invest Dermatol. 1999;112:72-77.
18. Wertz PW, van den Bergh B. The physical, chemical and functional properties of lipids in the skin and other biological barriers. Chem Phys Lipids. 1998;91:85-96.
19. Elias PM, Cullander C, Mauro T, et al. The secretory granular cell: the outermost granular cell as a specialized secretory cell. J Invest Dermatol Symp Oroc. 1998;3:87-100.
20. Elias PM. Barrier repair trumps immunology in the pathogenesis and therapy of atopic dermatitis. Drug Discov Today Dis Mech. 2008;5(1):e33-e38.
21. Van Scott EJ, Yu RJ. Control of keratinization with a-hydroxy acids and related compounds. Arch Dermtol. 1974;110: 586-590.
22. Middleton JD. Development of a skin cream designed to reduce dry and flaky skin. J Soc Cosmet Chem. 1974;25:519-534.
23. Alderson SG, Barratt MD, Black JG. Effect of 2-hydroxyacids on guinea-pig footpad statum corneum: mechanical properties and binding studies. Int J Cosm Sci. 1984;6:91-100.
24. Leyden JJ, Lavker RM, Grove G, et al. Alpha hydroxyl acids are more than moisturizers. J Geriatr Dermatol. 1995;3(suppl):33A-37A.
25. Lac-Hydrin (Ammonium Lactate) Lotion [package insert]. Princeton, NJ: Ranbaxy, Inc.; 2008.
26. Rawlings AV, Davies A, Cariomusto M, et al. Effect of lactic acid isomers on keratinocyte ceramide synthesis, stratum corneum lipid levels and stratum corneum barrier function. Arch Dermatol Res.1996;288(7):383-390.
27. Lavker RM, Kaidbey K, Leyden JJ. Effects of topical ammonium lactate on cutaneous atrophy from a potent topical corticosteroid. J Am Acad Dermatol. 1992;26:535-544.
28. Dahl MV, Dahl AC. 12% lactate lotion for the treatment of xerosis. Arch Dermatol.1983;119:27-30.
29. Menon GK, Elias PM, Feingold KR. Integrity of the permeability barrier is crucial for maintenance of the epidermal calcium gradient. Br J Dermatol. 1994;130: 139-147.
30. Mao-Qiang M, Feingold KR, Elias PM. Influence of exogenous lipids on permeability barrier recovery in acetone-treated murine skin. Arch Dermatol. 1993;129:728-738.
31. Mao-Qiang M, Brown BE, Wu-Pong S, et al. Exogenous nonphysiologic vs physiologic lipids. Arch Dermatol. 1995;131:809-816.
32. Chamlin SL, Kao J, Frieden IJ, et al. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol. 2002;47:198-208.
33. Sugarman JL, Parish LC. Efficacy of a lipid-based barrier repair formulation in moderate-to-severe pediatric atopic dermatitis. J Drugs Dermatol. 2009;8(12):1106-1111.
34. Madaan A. Epiceram for the treatment of atopic dermatitis. Drugs Today (Barc). 2008;44(10):751-755.